Companion Diagnostics: Technologies and Markets

Published - Nov 2013| Code - BIO077B| Analyst - Marianna Tcherpakov

Report Highlights

The global companion diagnostics market reached $1.1 billion in 2012. The market is expected to grow to $1.2 billion in 2013 and $3.5 billion in 2018 with a compound annual growth rate (CAGR) of 23.9%.

Report Includes

  • An overview of the market for companion diagnostics, including existing products on the market and detailed analysis of the competitive environments.
  • Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Examination of the current state of the industry, new technologies in assay development, and potential novel commercial venues in this area of the healthcare industry.
  • Identification of major commercial sectors in companion diagnostics: oncology related products vs. cardiovascular diseases and other segments.
  • Comprehensive company profiles of major players, as well as a list of current companies that have new companion diagnostics products in development.

Report Scope

Personalized medicine is relatively new to the market research report format and provides business tools to evaluate new commercial opportunities in diagnostics and biomarker fields. The geographic scope of this study covers U.S. and global companies. The report identifies major commercial sectors in companion diagnostics, including oncology-related products versus cardiovascular diseases. It describes current products in each area, identifies current market participants, and most importantly, notes the trends that are likely to affect further product development in this area. The report also provides information regarding less-developed sectors of this market, along with a list of current companies that have new companion diagnostic products in development.

Analyst Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology and industrial assay development and drug manufacturing. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.

Latest reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Title/Chapter Name Pages Price Member Price
Full Report: Companion Diagnostics: Technologies and Markets 187 $2,750 Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: SUMMARY2$250Free
Chapter- 3: OVERVIEW, STRUCTURE AND SIGNIFICANCE OF THE COMPANION DIAGNOSTICS INDUSTRY 17$250Free
Chapter- 4: BIOMARKER AND DIAGNOSTICS MARKETS AS THE BASIS FOR THE COMPANION DIAGNOSTICS INDUSTRY 8$118Free
Chapter- 5: EFFECT OF THE REGULATORY ASPECT, COST AND REIMBURSEMENT POLICIES ON THE COMPANION DIAGNOSTICS INDUSTRY6$88Free
Chapter- 6: EFFECT OF THE PERSONALIZED MEDICINE TREND ON PRODUCT DEVELOPMENT IN OTHER INDUSTRIES9$132Free
Chapter- 7: PATENT APPLICATIONS FOR COMPANION DIAGNOSTICS AND BIOMARKERS3$44Free
Chapter- 8: CURRENT TECHNIQUES AND TECHNOLOGIES FOR COMPANION DIAGNOSTICS6$88Free
Chapter- 9: GENETIC KNOWLEDGE AND CLINICIAN OPINIONS AS DRIVERS FOR THE COMPANION DIAGNOSTICS MARKET3$44Free
Chapter- 10: COMPANION DIAGNOSTICS INDUSTRY MARKET EVALUATIONQIAGEN17$250Free
Chapter- 11: COMPANION DIAGNOSTICS INDUSTRY OVERVIEW IN DIFFERENT RESEARCH AREAS88$1,294Free
Chapter- 12: MARKET SUMMARY 5$74Free
Chapter- 13: COMPANY PROFILES8$118Free
Chapter- 14: COMPANIES MENTIONED IN THIS REPORT12$176Free
Published - Nov-2010| Analyst - Marianna Tcherpakov| Code - BIO077A

Report Highlights

 
  • Oncotype Dx, although not FDA-approved, is still a lead product in the breast cancer diagnosis sector.  Oncotype Dx is reimbursed by most insurance companies and therefore enjoys an increase in its sales number every year.  Valued at $170 million in 2010, analysts believe that by 2015, Oncotype Dx for breast cancer risk recurrence and drug regimen may reach $300 million, a compound annual growth rate (CAGR) of 12%.
  • The approval of Selzentry for first time HIV patients is creating new opportunity for the assay Trofile, a companion diagnostic to Selzentry (Celsentri outside U.S.). As a result, Trofile is expected to reach an estimated $34 million by 2015, from $24 million in 2010, a compound annual growth rate (CAGR) of 7.2%.
RELATED REPORTS
Share This Report